A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: LiangHao Zhang
- Número de telefone: +86 18971498772
- E-mail: lianghao.zhang@maxvax.cn
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Participants must be 20 years of age or older as determined by the investigator at enrollment.
- Participants must be able to understand study procedures, risks, and benefits, provide voluntary agreement to participate in the study, and sign the informed consent form (ICF).
- Participants must be willing and able to attend all scheduled follow-up visits and comply with all requirements specified in the study protocol.
Females of childbearing potential must use highly effective contraception from 1 month prior to vaccination through 12 months following vaccination.
- Effective contraceptive methods include: oral contraceptives (excluding emergency contraceptives), contraceptive injections, subcutaneous implants, hormonal patches, intrauterine devices (IUDs), surgical sterilization, true abstinence, and condom use.
- Methods not considered effective include: rhythm method, withdrawal method, and emergency contraception.
Exclusion Criteria:
*Participants who meet any of the following criteria shall be ineligible for enrollment:
- Axillary body temperature ≥ 37.3 °C.
- History of respiratory syncytial virus (RSV) infection within 6 months prior to enrollment.
- New-onset respiratory infection symptoms within 7 days prior to enrollment, including cough, expectoration, dyspnea, wheezing, fever, rhinorrhea, and nasal obstruction.
- Presence of an acute illness or acute exacerbation of a chronic condition within 3 days prior to enrollment.
- Use of antipyretics and analgesics (excluding enteric-coated aspirin for the prevention of cardiovascular and cerebrovascular diseases) or antiallergic medications within 3 days prior to enrollment.
- Known hypersensitivity to any ingredient of the study vaccine, including Quillaja saponaria (QS-21), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), cholesterol, sucrose, sodium dihydrogen phosphate, anhydrous disodium hydrogen phosphate, polysorbate 80, sodium chloride, hydrochloric acid, and sodium hydroxide; history of severe allergic reactions or serious adverse events following any vaccination or drug administration, including anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local Arthus reaction, and severe urticaria.
- Pregnant female (positive urine pregnancy test), lactating female, or female with a pregnancy plan within 12 months following vaccination.
- Congenital asplenia, functional asplenia, or splenectomy due to any cause.
- Previous or current malignant neoplasm, with the exception of clinically cured carcinoma in situ and papillary thyroid carcinoma.
- Confirmed diagnosis of an autoimmune disease, including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, and autoimmune thyroid disease.
- Confirmed or suspected immunosuppression or immunodeficiency resulting from any cause, including primary or secondary immunocompromise, congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, or treatment with immunosuppressive or cytotoxic agents (e.g., chemotherapy, organ transplantation, or therapy for autoimmune diseases).
- Any condition that, in the investigator's judgment, would render intramuscular injection unsafe, such as a history of thrombocytopenia or other coagulation disorders.
- Previous or current serious clinical illness that is not cured (such as serious cardiovascular and cerebrovascular diseases, liver and kidney diseases, respiratory diseases, diabetes with complications, major surgery, etc.) may affect the evaluation of the trial.
- Previous or current thrombotic diseases.
- History of untreated tuberculosis or active tuberculosis infection at enrollment.
- Uncontrolled hypertension defined as systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg on measurement prior to vaccination.
- History of severe cardiac arrhythmia (e.g., atrial fibrillation).
- History or family history of convulsions, epilepsy, congenital brain malformation, psychiatric disorders, or other severe neurological conditions associated with cerebral nerve tissue injury, including brain tumor, cerebral hemorrhage, cerebral infarction (excluding lacunar cerebral infarction and cerebral infarction without sequelae), central nervous system infection, and chemical intoxication.
- History of any cognitive disorder or any moderate or severe condition causing cognitive impairment.
- Use of any investigational or unlicensed product (medicinal product, vaccine, or medical device) other than the study vaccine within 30 days prior to vaccination, or planned participation in another clinical trial during the study period.
- Administration of any inactivated vaccine within 14 days prior to vaccination, or any live vaccine within 28 days prior to vaccination.
- Prior receipt of any RSV vaccine.
- Administration of immunoglobulin and/or any blood or plasma derivative (e.g., gamma globulin, intravenous immunoglobulin) within 3 months prior to vaccination, or planned administration during the study period.
- Long-term use (consecutive use > 14 days) of immunosuppressive or other immunomodulatory agents within 3 months prior to vaccination or planned use during the study period. Systemic glucocorticoids ≥ 20 mg prednisone or equivalent daily for ≥ 14 days are considered long-term use. Topical preparations (ointments, eye drops, inhalations, nasal sprays) at doses not exceeding those recommended in the package insert are permitted.
- Use of long-acting immunomodulatory agents (e.g., infliximab) within 6 months prior to vaccination or planned use during the study period.
- History of chronic alcohol abuse and/or drug abuse that, in the investigator's judgment, may interfere with study assessments.
- Planned migration during the study period that would preclude completion of all study procedures.
- Any other condition that, in the investigator's judgment, may interfere with the validity of study evaluations, with special attention to respiratory infection symptoms.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Vaccine Group
Participants will receive single dose of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), by IM injection into the deltoid muscle of the upper arm.
|
0,5 mL por dose
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Neutralizing Antibodies against both the RSV-A and RSV-B subtypes.
Prazo: At pre-vaccination (Day 1), and at 1, 12, and 24 months post-vaccination.
|
Measured by Virus Neutralization Test.
|
At pre-vaccination (Day 1), and at 1, 12, and 24 months post-vaccination.
|
|
Specific IgG Antibodies to RSV pre-F of both RSV-A and RSV-B subtypes.
Prazo: At pre-vaccination (Day 1), and at 1 month, 12 months, and 24 months post-vaccination.
|
Measured by ELISA.
|
At pre-vaccination (Day 1), and at 1 month, 12 months, and 24 months post-vaccination.
|
|
The Frequency of RSV pre-F Specific Cluster of Differentiation 4+ (CD4+) T Cells or Cluster of Differentiation 8+ (CD8+) T cells Expressing.
Prazo: At pre-vaccination (Day 1), and at 1 month, 12 months, and 24 months post-vaccination.
|
Among markers expressed were interleukin-2 (IL-2), cluster of 40 ligand (CD40L), tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSV-PreF peptide preparations.
Measured by Intracellular Cytokine Staining (ICS).
|
At pre-vaccination (Day 1), and at 1 month, 12 months, and 24 months post-vaccination.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
Outros números de identificação do estudo
- MKKCT-900-005
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .